Novo Nordisk (NJ) Appoints Robert Clark as Vice President, Regulatory Affairs
Published: May 09, 2012
PRINCETON, N.J., May 8, 2012 /PRNewswire/ -- Novo Nordisk Inc., a global healthcare company with 89 years of innovation and leadership in diabetes care, announced today that Robert Clark will be joining the company's U.S. business as Vice President, Regulatory Affairs starting May 14.
Clark will lead Novo Nordisk's U.S. regulatory team, and maintain relationships with key individuals and agencies outside of Novo Nordisk that play a specific role in the U.S. Food and Drug Administration's (FDA) review and approval process.
"Bob is bringing 27 years of experience and knowledge of the global and US regulatory environment, and it's that know-how we require for an increasingly complex pharmaceutical marketplace," says Anne Philips, M.D., Corporate Vice President, Clinical Development, Medical and Regulatory Affairs, Novo Nordisk Inc. "Novo Nordisk has one of the most promising diabetes pipelines in the industry, and having a respected leader known to regulatory authorities will help us achieve our ongoing mission to bring new therapies to patients."
Clark comes to Novo Nordisk from Pfizer, where he was U.S. Regulatory Strategy Head. During his time at Pfizer, he led or supported approvals of new medicines in cardiovascular, endocrine, women's health and anti-infective therapy areas. Additionally, he is a nationally-recognized expert on U.S. pharmaceutical advertising and promotional practices.
Clark holds a Master's in Science in Pharmacology from the New York Medical College.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit http://www.novonordisk-us.com and follow us on Twitter @novonordiskus.
SOURCE Novo Nordisk